Pharma- biotech- Patent Commercialisation

The Nagoya Protocol – Convention on Biological Diversity

21st July, 2014 - 9:10 am Categories: News & Updates Patent Commercialisation Patents Pharma- biotech- Patent Commercialisation

0 Comments

A new international treaty named the “Nagoya Protocol” will be giving some relief to India and other developing countries. The Nagoya Protocol on Access to Genetic Resources with an objective of ensuring access of genetic resources to the signatory countries and ensuring fair and equitable sharing of benefit to the local community and signatory country that … Continue reading The Nagoya Protocol – Convention on Biological Diversity

Two-Days International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios

13th December, 2013 - 7:42 am Categories: Educational Conferences/ Seminar News & Updates Pharma- biotech- Patent Commercialisation

0 Comments

We are happy to inform you all that IIPRD and Khurana & Khurana, in association with Cantor Colburn (US) and Fukami Patent Office (Japan) are holding an International Patent Symposium covering all major and relevant Pharmaceutical/Biotechnology Related Patent issues in the month of February, 2014 in India. The Two-Days International Symposium would be covering Strategies for Managing … Continue reading Two-Days International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios

Inventors, All Technologies Aren’t Worth Billions

31st July, 2011 - 6:23 pm Categories: Hi Tech Patent Commercialisation Patent Commercialisation Pharma- biotech- Patent Commercialisation

0 Comments

Working in the IP/Technology Commercialization and Out-Licensing domain makes you assess and evaluate commercial viability of numerous IP backed inventions across technology domains. Apart from learning about and assessing new technologies, we also tend to learn quite of lot about Inventors mindset, specifically about their perspective of their own inventions. This article relates to our … Continue reading Inventors, All Technologies Aren’t Worth Billions

Anti Cancer drug: Making it Patient-driven, not Disease-driven

11th April, 2011 - 10:16 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

0 Comments

Introduction: French compatriots Ipsen and bioMérieux, have been few most potential companies, since 2007 in the development of companion assay to assess patient benefit from a compound useful for treating several severe forms of cancers.Partnership between two companies has focused on the two main broad areas of pharma research: Personalized medicine and Theronostics. Personalized medicine … Continue reading Anti Cancer drug: Making it Patient-driven, not Disease-driven

Category: Pharma- biotech- Patent Commercialisation

The Nagoya Protocol – Convention on Biological Diversity

Two-Days International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios

Inventors, All Technologies Aren’t Worth Billions

Anti Cancer drug: Making it Patient-driven, not Disease-driven

Categories

Archives